Notably, two preclinical studies have demonstrated that inhibition of excessive cerebral KLK8 by intraventricular anti-KLK8 antibody delivery can enhance neuroplasticity, reverse molecular signatures of anxiety, and ultimately improve memory and reduce fear in Alzheimer’s disease mouse model [36, 39]. Here, KLK8 is linked to early-onset autosomal dominant Alzheimer disease.